Medipattern™ Corporation Signs OEM Agreement With iPACS(TM) LLC

TORONTO, ONTARIO--(Marketwire - December 22, 2008) - Attention: Business/Financial Editors

The Medipattern Corporation (TSX VENTURE: MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, and iPACS.US, LLC, a market innovator in value added Picture and Archive Communications Systems (PACS) are pleased to announce the signing of a non-exclusive original equipment manufacturing (OEM) agreement allowing iPACS to integrate B-CAD into its product line. iPACS offers a full line of radiology imaging archiving and routing solutions that provide rapid access to images. iPACS is on the forefront of CAD driven workflow, with current product offerings integrating to CAD for Breast Cancer on other modalities, CAD for Prostate Cancer and CAD packages for Oncology. B-CAD expands the iPACS CAD module to aid diagnosticians when reading breast ultrasound exams.

“iPACS’ current customers include Orange Coast Memorial Medical Center, Medical Imaging of Southern California, Pacific Breast Imaging, Nassau Radiology and Suffolk Medical Imaging. One of iPACS’ strengths is in improved communications between sites and in easy storage solutions,” stated Henry Wyszomierski, CEO of iPACS. “B-CAD helps us to organize patient information in a consolidated record saving time and provides detailed reports aiding diagnosticians as they work with sonographers logged into our system. B-CAD’s digital reporting makes working with distributed sites possible. In addition, it provides computer aided detection to give that CAD second opinion. Breast care centers using B-CAD are currently being reimbursed by 33 payers. B-CAD is a valuable addition for our PACS system.”

“We congratulate iPACS on its savvy business model offering PACS for either a fixed fee or on a fee per case ASP model which makes their products accessible to all market niches from small centers through larger organizations like Nassau Radiology with nine facilities in New York State,” commented Jeff Collins, CEO of The Medipattern Corporation. “The key is in maintaining the standard of care across this array of facilities. iPACS’ proprietary approach gathers all the information for the patient study and quickly communicates it with reading radiologists allowing them to team read from many facilities to ensure exceptional patient care. B-CAD plays a major role in this strategy through providing consistent reporting while increasing efficiency, productivity and improving the overall effectiveness of the medical professionals who work to help the millions of women at risk of breast cancer each year. Medipattern and iPACS plan to co-market B-CAD into iPACS’ installed base as well as promote B-CAD in iPACS’ developing business endeavors. We continue to pursue other OEM relationships in order to broaden our sales channels and increase our ability to expand B-CAD into new markets and indications.”

Upcoming Events:

- AIUM, April 2-5, 2009 in NYC, NY

- BIC, May 25-28, 2009 in Anaheim, CA

- SDMS, October 15-18, 2009 in Nashville, TN

- RSNA, November 29-December 3, 2009 in Chicago, IL

About The Medipattern Corporation:

Medipattern® is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company’s website at: www.medipattern.com.

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern’s performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern’s current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “potential”, and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company’s corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.